Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E.
Target Price
The average target price of EGTX.ST is 10.0 and suggests 86% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell